Skip to main content
COVID-19 is an emerging, rapidly evolving situation.

Get the latest public health information from CDC:
Get the latest research information from NIH:

Profile Image

Senior Investigator

Daniel Samuel Pine, M.D.

Emotion and Development Branch
Building 1 Room B310-0135
1 Center Drive MSC0135
Bethesda MD 20895-0135
Office: (301) 594-1318

Dr. Pine received his B.A. in anthropology from Grinnell College in 1985 and his M.D. from the University of Chicago Pritzker School of Medicine in 1990. He completed an internship in pediatrics, a residency in general psychiatry, and fellowships in both child psychiatry and child psychiatry research at the College of Physicians and Surgeons of Columbia University and the New York State Psychiatric Institute. Dr. Pine held both junior and senior faculty positions at Columbia, where he studied epidemiology, psychobiology, and therapeutics of childhood mood and anxiety disorders, working with David Shaffer, Patricia Cohen, as well as Donald and Rachel Klein. In 2000, he moved to the Mood and Anxiety Disorders Program within the NIMH as Chief of the Section on Development and Affective Neuroscience. Dr. Pine received a NARSAD Independent Investigator Award, a NIMH Career Development Award and the Blanche Ittelson Award from the American Psychiatric Association. His laboratory investigates the neural and psychological correlates of pediatric mood and anxiety disorders.

The Section on Development and Affective Neuroscience examines the relationships among brain development, emotion regulation, and risk for mood and anxiety disorders in children and adolescents. The broad goal of research conducted within the section is to define the manner in which developmental changes in brain function relate to normal changes in emotion regulation during development and to mood or anxiety disorders manifest in children and adolescents. To accomplish this goal, the section emphasizes application of fMRI to questions on emotional development, performing fMRI studies using various traditional paradigms from cognitive and affective neuroscience. However, fMRI provides only one tool used to define the manner in which changes in brain systems relate to development and to manifestations of mood and anxiety disroders across the lifespan. Other projects will use behavioral measures of emotion regulation, genetically-informative research designs, and treatment strategies. This will include studies examining changes in brain structure and function during treatment for a mood or anxiety disorder. Overall, the planned studies will answer questions in children and adolescents on neural correlates of developmental changes in emotional regulation, risk or symptom patterns in mood and anxiety disorders, as well as the effects of treatments for mood and anxiety disorders on the developing brain.

Clinical Protocol

  • Fluoxetine's effects on vigilance and emotional memory in anxious and depressed youth ( 01-M-0192 )

  • Adolescence, Puberty, and Emotion Regulation: An fMRI Study ( 01-M-0152 )

Staff Image
  • Monique Ernst, M.D., Ph.D.
    Staff Clinician

  • Eric Nelson, Ph.D.
    Staff Scientist

  • 1) Guyer AE, Choate VR, Detloff A, Benson B, Nelson EE, Perez-Edgar K, Fox NA, Pine DS (2012)
  • Ernst M: Striatal functional alterations during incentive anticipation in pediatric anxiety disorders
  • Am J Psychiatry
  • 2) Blair K, Geraci M, Korelitz K, Otero M, Towbin K, Ernst M, Leibenluft E, Blair RJR, Pine DS (2012)
  • The pathology of social phobia is independent of developmental changes in face processing
  • Am J Psychiatry
  • 3) Lau JYF, Britton JC, Nelson EE, Angold A, Ernst M, Goldwin M, Grillon C, Leibenluft E, Lissek S, Norcross M, Shiffrin N, Pine DS (2012)
  • Distinct neural signatures of threat learning in adolescents and adults
  • Proc Natl Acad Sci USA
  • 4) Beesdo K, Lau J, McClure-Tone EB, Guyer AE, Monk CS, Neslon EE, Fromm SJ, Goldwin MA, Wittchen H-U, Leibenluft E, Ernst M, Pine DS (2009)
  • Common and specific amygdala-function perturbations in depressed versus anxious adolescents
  • Arch Gen Psychiatry , 66, 275-85
  • 5) Pine DS, Helfinstein SM, Bar-Haim Y, Nelson E, Fox NA (2009)
  • Challenges in developing novel treatments for childhood disorders: lessons from research on anxiety
  • Neuropsychopharmacology , 34, 213-28
  • 6) Guyer AE, Lau JYF, McClure-Tone EB, Parrish J, Shiffrin ND, Reynolds RC, Chen G, Blair RJR, Leibenluft E, Fox NA, Ernst M, Pine DS, Nelson EE (2008)
  • Amygdala and vlPFC function during anticipated peer evaluation in pediatric social anxiety
  • Arch Gen Psychiatry, 65, 1303-12
  • 7) Blair K, Geraci M, Devido J, McCaffrey D, Chen G, Vythilingam M, Ng P, Hollon N, Jones M, Blair RJR, Pine DS (2008)
  • The neural response to self-and- other-referential praise and criticism in generalized social phobia
  • Arch Gen Psychiatry , 65, 1176-84
  • 8) Pine DS, (corresponding author) (2001)
  • An eight-week placebo-controlled trail of fluoxemine for anxiety disorders in children and adolescents.
  • N Eng J Med, 344, 1279-1285
  • 9) Pine DS,Grun J, Maguire EA, Burgess N, Zarahn E, Koda V, Fyer A, Szeszko PR, Bilder RM (2001)
  • Neurodevelopmental aspects of virtual reality navigation: an fMRI study
  • NeuroImage
  • 10) Pine DS, Fyer A, Grun J, Phelphs EA, Szeszko PR, Koda V, Ardekani B, Maguire EA, Burgess N, Bilder RM (2001)
  • Methods for developmental studies of fear conditioning circuitry.
  • Biol Psychiatry
  • 11) Pine DS, Klein RG, Coplan JD, Martinez J, Kovalanko P, Moreau D, Klein DF, Gorman JM (2000)
  • Differential sensitivity to CO2 in childhood anxiety disorders.
  • Arch Gen Psychiatry, 57, 960-967
  • 12) Pine DS, Wasserman G, Wolk S (1999)
  • Memory and anxiety in pre-pubertal boys at risk for delinquency.
  • J Am Acad Child Adolesc Psychiatry, 38, 1024-1031
  • 13) Pine DS, Cohen P, Gurley D, Brook J, Ma Y (1998)
  • The risk for early-adulthood anxiety and depressive disorders in adolescents with anxiety and depressive disorders.
  • Arch Gen Psychiatry, 55, 56-64
View Pubmed Publication